There is no eligible RCT to compare the different initial doses for glargine U‐300, degludec U‐100, or NPH to control blood glucose with acceptable side effects for adult patients with T2DM who require basal insulin therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.